The global small-scale bioreactors market was surpassed at USD 1.69 billion in 2022 and is expected to hit around USD 6.72 billion by 2032, growing at a CAGR of 14.8% from 2023 to 2032.
Report Scope of the Small-scale Bioreactors Market
|Market Size in 2022||USD 1.69 billion|
|Revenue Forecast by 2032||USD 6.72 billion|
|Growth rate from 2023 to 2032||CAGR of 14.8%|
|Forecast Period||2023 to 2032|
|Market Analysis (Terms Used)||Value (US$ Million/Billion) or (Volume/Units)|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Companies Covered||Sartorius AG; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corp.; Lonza Group; Eppendorf AG; Miltenyi Biotec; Getinge AB; Solaris Biotechnology Srl; Infors AG|
The key drivers responsible for the market growth include the wide-scale product usage in the pharmaceutical industry along with portfolio expansion by major players. Small-scale bioreactors are essential for the development and optimization of processes, therefore they are frequently used in pharmaceutical and biopharmaceutical research. These bioprocessing equipment are generally used for small-scale production and range in size from a few milliliters to 5-10 L. The COVID-19 pandemic has witnessed an increased demand as a result of the sudden rise in COVID-19 cases.
The sales of small-scale bioreactors significantly increased in 2020 and 2021 as a result of numerous businesses expanding their facilities to carry out R&D for COVID-19 vaccines. Moreover, the worldwide immunization campaigns around the globe and the rising demand are expected to increase product sales during the forecast period. In addition, heavy investments by government authorities to improve biopharmaceutical research and the development of a vaccine are also influencing the industry’s growth. For instance, the South Korean government allocated USD 250 million in April 2020 to launch the Vaccine Innovative Technology Alliance (VITAL), which will help with vaccine research, production, and use. To make South Korea the fifth-largest vaccine manufacturer throughout the globe by 2025 and reach 80% vaccine self-sufficiency, the nation has spent an additional $2 billion on the K Vaccine program.
Moreover, the rising prevalence of chronic diseases, such as cancer, cardiac disease, diabetes, and hypertension, has led to more focus on the development of innovative biological therapies. Similarly, the demand for monoclonal antibodies as well as personalized medicines has increased bioproduction, accelerating small-scale bioreactor demand. Furthermore, the rising usage of high-end technologies to simplify complex manufacturing will enhance the demand for small-scale bioreactors during the forecast period. In addition, the high investments in research and development activities by key biopharmaceutical companies are expected to drive industry growth. For instance, in august 2021, PBS Biotech, a manufacturer of single-use bioprocessing devices, completed a USD 10 million private financing round with BroadOak Capital Partners.
With the funds, the company will have the opportunity to grow and commercialize its line of single-use bioreactor devices and outsourced process design services. Due to the demand for superior quality and better efficiency in drug manufacturing, the biopharmaceutical industry is quickly shifting toward the use of single-use bioprocessing systems with integrated real-time monitoring and technical analysis that can facilitate automation, enhance data-driven quality control, and continue driving performance. Therefore, it is expected that the shift toward advanced bioprocessing technology devices, such as small-scale bioreactors, will propel the growth of this market.
Small-scale Bioreactors Market Segmentations: